Individuals who indicated their willingness to participate in the research and did not have a history of any other hematologic or liver conditions, such as COVID-19, Epstein-Barr virus, hepatitis B, hepatitis C, or human immunodeficiency virus, were considered eligible
Ketamine and rapid-acting antidepressants: a window into a new neurobiology for mood disorder therapeutics
Private insurance coverage varies dramatically
While definitive causal reduction in cancer risk with GLP-1 therapies is not established, the cardiovascular and metabolic benefits of significant weight loss may outweigh theoretical cancer concerns for many patients
Telehealth/Weight Loss Platforms Hims/Hers, Ro, Calibrate/Found Valuation: 3-5x revenue at $15-20M revenue = $45-100M exit 3